Please use this identifier to cite or link to this item:
|Title:||Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6)|
|Authors:||Correa-Silva, Silvia R. [UNIFESP]|
Nascif, Sergio O. [UNIFESP]
Molica, Patricia [UNIFESP]
Sa, Larissa Bianca Paiva Cunha de [UNIFESP]
Vieira, Jose G. H. [UNIFESP]
Lengyel, Ana-Maria J. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
|Citation:||Clinical Endocrinology. Malden: Wiley-Blackwell Publishing, Inc, v. 72, n. 1, p. 70-75, 2010.|
|Abstract:||P>BackgroundIn Cushing's disease (CD), adrenocorticotrophic hormone (ACTH)/cortisol responses to growth hormone secretagogues (GHS), such as ghrelin and GHRP-6, are exaggerated. the effect of clinical treatment of hypercortisolism with ketoconazole on ACTH secretion in CD is controversial. There are no studies evaluating ACTH/cortisol responses to GHS after prolonged ketoconazole use in these patients.ObjectiveTo compare ghrelin- and GHRP-6-induced ACTH/cortisol release before and after ketoconazole treatment in patients with CD.Design/patientsEight untreated patients with CD (BMI: 28 center dot 5 +/- 0 center dot 8 kg/m2) were evaluated before and after 3 and 6 months of ketoconazole treatment and compared with 11 controls (BMI: 25 center dot 0 +/- 0 center dot 8).ResultsAfter ketoconazole use, mean urinary free cortisol values decreased significantly (before: 613 center dot 6 +/- 95 center dot 2 nmol/24 h; 3rd month: 170 center dot 0 +/- 27 center dot 9; 6th month: 107 center dot 9 +/- 30 center dot 1). the same was observed with basal serum cortisol (before: 612 center dot 5 +/- 69 center dot 0 nmol/l; 3rd month: 463 center dot 5 +/- 44 center dot 1; 6th month: 402 center dot 8 +/- 44 center dot 1) and ghrelin- and GHRP-6-stimulated peak cortisol levels (before: 1183 center dot 6 +/- 137 center dot 9 and 1045 center dot 7 +/- 132 center dot 4; 3rd month: 637 center dot 3 +/- 69 center dot 0 and 767 center dot 0 +/- 91 center dot 0; 6th month: 689 center dot 8 +/- 74 center dot 5 and 571 center dot 1 +/- 71 center dot 7 respectively). An increase in basal ACTH (before: 11 center dot 2 +/- 1 center dot 6 pmol/l; 6th month: 19 center dot 4 +/- 2 center dot 7) and in ghrelin-stimulated peak ACTH values occurred after 6 months (before: 59 center dot 8 +/- 15 center dot 4; 6th month: 112 center dot 0 +/- 11 center dot 2). GHRP-6-induced ACTH release also increased (before: 60 center dot 7 +/- 17 center dot 2; 6th month: 78 center dot 5 +/- 12 center dot 1), although not significantly.ConclusionsThe rise in basal ACTH levels during ketoconazole treatment in CD could be because of the activation of normal corticotrophs, which were earlier suppressed by hypercortisolism. the enhanced ACTH responses to ghrelin after ketoconazole in CD could also be due to activation of the hypothalamic-pituitary-adrenal axis and/or to an increase in GHS-receptors expression in the corticotroph adenoma, consequent to reductions in circulating glucocorticoids.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.